Adaptimmune Therapeutics plc (ADAP)
NASDAQ: ADAP · IEX Real-Time Price · USD
1.170
-0.010 (-0.85%)
At close: Jul 19, 2024, 4:00 PM
1.080
-0.090 (-7.69%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Adaptimmune Therapeutics Revenue
Adaptimmune Therapeutics had revenue of $18.36M in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $5.68M. In the year 2023, Adaptimmune Therapeutics had annual revenue of $60.28M with 122.05% growth.
Revenue (ttm)
$18.36M
Revenue Growth
-74.21%
P/S Ratio
16.28
Revenue / Employee
$40,886
Employees
449
Market Cap
298.93M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 60.28M | 33.13M | 122.05% |
Dec 31, 2022 | 27.15M | 21.00M | 341.50% |
Dec 31, 2021 | 6.15M | 2.19M | 55.36% |
Dec 31, 2020 | 3.96M | 2.84M | 252.76% |
Dec 31, 2019 | 1.12M | -58.38M | -98.11% |
Dec 31, 2018 | 59.51M | 21.67M | 57.28% |
Dec 31, 2017 | 37.83M | 23.64M | 166.47% |
Dec 31, 2016 | 14.20M | 4.33M | 43.84% |
Jun 30, 2015 | 9.87M | 9.05M | 1,096.48% |
Jun 30, 2014 | 825.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Tactile Systems Technology | 276.67M |
Alimera Sciences | 90.22M |
Poseida Therapeutics | 82.50M |
Enanta Pharmaceuticals | 72.88M |
SOPHiA GENETICS | 64.18M |
Aquestive Therapeutics | 51.50M |
Verrica Pharmaceuticals | 8.91M |
Opthea | 385.28K |
ADAP News
- 4 weeks ago - ADAP: Initiating Coverage of Adaptimmune, a Leading T-Cell Therapy Company - Benzinga
- 6 weeks ago - Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise - Newsfile Corp
- 7 weeks ago - Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications - GlobeNewsWire
- 7 weeks ago - Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications - Newsfile Corp
- 2 months ago - Adaptimmune Reports Q1 2024 Financial and Business Updates - Newsfile Corp
- 2 months ago - Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital - Newsfile Corp
- 2 months ago - Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024 - Newsfile Corp
- 3 months ago - Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated - Newsfile Corp